About
Spun out of Weizmann institute for Science in 2013, the company utilize RNA interference technology based on the robust scientific discoveries where a deep understanding of the biology behind microRNAs involvement in central nervous system (CNS) related disorders, was gained.
Lead Program
Treatment resistant depression therapy. A novel RNA interference proprietary targeting key mRNAs involved in depression.
Based in miR-135
which was demonstrated to act as a key modulator of depression and anxiety in numerous models
Selective
No reduction of post-synaptic HTR1A
Facilitates
Serotonin increase in the brain
Technology
Non-invasive brain delivery
Dual activity
Modulates both Serotonin transporter and serotonin auto receptor
Precision medicine
With neuron targeting specifically in the dorsal raphe nucleolus
High profile
Immunological safety
Technology
miCure owns a technology of a non-invasive brain delivery of oligonucleotides like siRNAs, miRNAs and ASOs that allows targeting gene expression modulation in specific cell types (pathology related population). The technology is based on linking the oligonucleotide of interest to a ligand of a neurotransmitter transporter and was demonstrated to be effective in NHP studies.
Literature
News
miCure Therapeutic secured a two million dollar seed investment from private investors
miCure Therapeutics is a leading-edge biotech company established in September 2013 in the Science Park of Ness Ziona, Israel. The company is focused on micro-RNA
miCure Therapeutics acquired key oligonucleodites patents fron nLife Therapeutics
miCure Therapeutics is a leading-edge biotech company focused on micro-RNA therapeutics and diagnostics for the central nervous system. Current development program based on mir135 mimic
Phone
+34663885719
Email Address
info@micurerx.com
Address
Amot Investment Tower, 2 Weizmann St., 24th Floor Tel-Aviv 6423902 , Israel